Abstract
Despite treatment with supra-physiological doses of pancreatic enzyme supplements, residual steatorrhoea is a common problem in patients with cystic fibrosis (CF) and pancreatic insufficiency. Strategies to enhance the activity of pancreatic enzymes include decreasing duodenal acidity. The aim of this study was to evaluate the effect of omeprazole (Losec), a proton-pump inhibitor, on fat absorption in CF patients with residual steatorrhoea despite high dose pancreatic enzyme supplements (≥10,000 U lipase/kg per day). A random cross-over design was chosen. Fat digestion was evaluated with and without omeprazole by means of chemical fat measurements in 3-day stool collections together with 3-day weighed food records for calculation of fat absorption. The results of 15 patients (3 girls and 12 boys) with confirmed steatorrhoea during the control evaluation were analysed. Median age was 8.7 years (range 3.5–15.9 years). Median daily lipase intake was 13,500 U/kg per day (range 10,000–22,000 U/kg per day). During treatment with omeprazole, median faecal fat loss (g fat/day) decreased from 13 g (quartiles 11.5–16.5 g/day) to 5.5 g (quartiles 4.9–8.1 g/day) (P <0.01). The same improvement was noted when fat absorption was calculated: 87% (quartiles 81–89%) without versus 94% (quartiles 90–96%) with omeprazole (P <0.001). Conclusion:omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution.
Similar content being viewed by others
Abbreviations
- CF :
-
cystic fibrosis
- PI :
-
pancreatic insufficiency
References
Barraclough M, Taylor CJ (1996) Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic function and fat absorption. J Pediatr Gastroenterol Nutr 23: 45–50
Borowitz DS, Grand RJ, Durie PR (1995) Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus committee. J Pediatr 127: 681–684
Borowitz DS, Baker RD, Stallings V (2002) Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 35: 246–259
Bruno MJ, Rauws EAJ, Hoek FJ, Tytgat GN (1994) Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Dig Dis Sci 39: 988–992
Durie PR, Bell L, Linton W, Corey ML, Forstner GG (1980) Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 21: 778–786
Francisco MP, Wagner MH, Sherman JM, Theriaque D, Bowser E, Novak DA (2002) Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 35: 79–83
Gaskin KJ, Durie PR, Corey M, Wei P, Forstner GG (1982) Evidence for a primary defect of pancreatic HCO3 secretion in cystic fibrosis. Pediatr Res 16: 554–557
Graham D (1982) Pancreatic enzyme replacement. The effect of antacids or cimetidine. Dig Dis Sci 27: 484–490
Heijerman HG, Lamers CB, Bakker W (1991) Omeprazole enhances the efficacy of pancreatine (Pancrease) in cystic fibrosis. Ann Int Med 14: 200–201
Heijerman HGM, Lamers CB, Bakker W, Dijkman JH (1993) Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas. Dig Dis Sci 38: 1–6
Hendriks JJE, Kester ADM, Donckerwolcke R, Forget PP, Wouters EF (2001) Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 33: 260–265
Hernandez M, Castellet J, Narval JL, Rincon JM, Ruiz J, Sánchez E, Sobradillo B, Zuzimendi A (1988) Curvas y tabals de crecimiento. Fundacion F Obregozo, Bilbao. Ed Garsi, Madrid
Kalivianakis M, Minich DM, Bijleveld CMA, van Aalderen WM, Stellaard F, Laseur M, Vonk RJ, Verkade HJ (1999) Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 69: 127–134
Littlewood JM, Wolfe SP (2000) Control of malabsorption in cystic fibrosis. Paediatr Drugs 2: 205–222
Robinson P, Sly PD (1990) Placebo-controlled trial of misoprostol in cystic fibrosis. J Pediatr Gastroenterol Nutr 11: 37–40
Robinson PJ, Sly PD, Smith AL (1988) Effect of misoprostol on fat malabsorption in cystic fibrosis. Arch Dis Child 63: 1081–1082
Robinson PJ, Smith AL, Sly PD (1990) Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci 35: 1299–1304
Stead RJ, Skypala I, Hodson ME, Batten JC (1987) Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 42: 533–537
Tran TM, Van den Neucker A, Hendriks JJE, Forget P, Forget PP (1998) Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatr 87: 553–558
Van de Kamer JH, Ten Bokkel-Huinink H, Weyers HA (1949) Rapid method for the determination of fat in feces. J Biol Chem 177: 348–355
Walters MP, Kelleher J, Gilbert J, Littlewood JM (1990) Clinical monitoring of steatorrhoea in cystic fibrosis. Arch Dis Child 65: 99–102
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Proesmans, M., De Boeck, K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr 162, 760–763 (2003). https://doi.org/10.1007/s00431-003-1309-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-003-1309-5